Navigation Links
Steroid Fails to Ease Meningitis in Trials
Date:12/12/2007

ncy/article/000680.htm" target="_new">U.S. National Library of Medicine.



SOURCES: Matthew Scarborough, M.D., senior lecturer in infectious diseases, John Radcliffe Hospital, Oxford, England, and College of Medicine/Malawi-Liverpool-Wellcome Programme of Clincal Tropical Research, Blantyre, Malawi; Dean A. Blumberg, M.D., associate professor of pediatric infectious diseases, University of California, Davis; Dec. 13, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Steroids Seem Safe for Babies at Risk of Early Birth
2. Batters may achieve dramatic increases in home runs through steroids
3. Repeat steroids to premature infants linked to cerebral palsy
4. Multiple corticosteroid injections in pregnant women may increase cerebral palsy
5. International Law Enforcement Operation Targets Underground Manufacture of Anabolic Steroids
6. Steroids Are Abused for Skin, Not Just Muscles
7. Research Indicates Nearly 25 Percent of Supplements Are Contaminated With Steroids, Stimulants and Banned Substances
8. Federal research plan to determine nanotech risks fails to deliver
9. States HMO Report Card Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability
10. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
11. Experimental Drug Fails Against Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Steroid Fails to Ease Meningitis in Trials
Steroid Fails to Ease Meningitis in Trials
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 1PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 2PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 1Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 4Back to normal 3A Surgery improves outcomes for spine patients 47438 1Back to normal 3A Surgery improves outcomes for spine patients 47438 2